410 related articles for article (PubMed ID: 17726795)
1. Rosiglitazone + glimepiride: new drug. Another combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17726795
[No Abstract] [Full Text] [Related]
2. Rosiglitazone/glimepiride (Avandaryl) for diabetes.
Med Lett Drugs Ther; 2006 Mar; 48(1230):22-4. PubMed ID: 16538189
[No Abstract] [Full Text] [Related]
3. Pioglitazone + glimepiride: a combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):145. PubMed ID: 17724836
[No Abstract] [Full Text] [Related]
4. Pioglitazone/glimepiride (Duetact) for diabetes.
Med Lett Drugs Ther; 2007 Jan; 49(1253):9-11. PubMed ID: 17261966
[No Abstract] [Full Text] [Related]
5. Treating type 2 diabetes: targeting the many causative factors.
Sutherland JE; Hoehns JD
J Fam Pract; 2004 May; 53(5):376-88. PubMed ID: 15125823
[No Abstract] [Full Text] [Related]
6. Drugs for type 2 diabetes.
Treat Guidel Med Lett; 2008 Jul; 6(71):47-54. PubMed ID: 18583949
[No Abstract] [Full Text] [Related]
7. Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study.
Herman WH; Dirani RG; Horblyuk R; O'Neill MC; Kravitz B; Heise MA; Bakst A; Freed MI;
Am J Manag Care; 2005 Apr; 11(4):273-8. PubMed ID: 15839187
[TBL] [Abstract][Full Text] [Related]
8. Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea.
Thayer S; Arondekar B; Harley C; Darkow TE
Ann Pharmacother; 2010 May; 44(5):791-9. PubMed ID: 20371759
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone hydrochloride/glimepiride.
Blake EW
Drugs Today (Barc); 2007 Jul; 43(7):487-97. PubMed ID: 17728849
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients.
Tseng CH; Huang TS
Diabetes Res Clin Pract; 2005 Nov; 70(2):193-4. PubMed ID: 16188579
[No Abstract] [Full Text] [Related]
11. Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes.
Charbonnel B
Int J Clin Pract Suppl; 2007 Jun; (153):1-2. PubMed ID: 17594387
[No Abstract] [Full Text] [Related]
12. Insulin initiation in Type 2 diabetes.
Page S
Diabet Med; 2005 Sep; 22 Suppl 4():2-5. PubMed ID: 16109011
[No Abstract] [Full Text] [Related]
13. Pioglitazone/metformin (Actoplus met).
Med Lett Drugs Ther; 2006 Jan; 48(1227):9-11. PubMed ID: 16444136
[No Abstract] [Full Text] [Related]
14. [Warning signals insulin resistance. Insulin resistance causes not only diabetes].
MMW Fortschr Med; 2004 Jul; 146(29-30):49. PubMed ID: 15540564
[No Abstract] [Full Text] [Related]
15. The therapeutic efficacy of rosiglitazone is enhanced in sulphonylurea-treated patients with type 2 diabetes.
Itakura H; Abbasi F; Lamendola C; Basina M; Reaven G
Diabetes Obes Metab; 2008 Aug; 10(8):685-7. PubMed ID: 18476981
[No Abstract] [Full Text] [Related]
16. [Sulfonylurea-pioglitazone combination agent].
Hashiramoto M; Kaku K
Nihon Rinsho; 2012 May; 70 Suppl 3():633-41. PubMed ID: 22768590
[No Abstract] [Full Text] [Related]
17. Pioglitazone plus glimepiride: a promising alternative in metabolic control.
Derosa G
Int J Clin Pract Suppl; 2007 Jun; (153):28-36. PubMed ID: 17594391
[TBL] [Abstract][Full Text] [Related]
18. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
19. Which oral drug is right for your type 2 diabetes? New thinking on oral drug combinations that can provide better glycemic control.
Health News; 2005 Feb; 11(2):10-1. PubMed ID: 15732153
[No Abstract] [Full Text] [Related]
20. Glimepiride for NIDDM.
Med Lett Drugs Ther; 1996 May; 38(975):47-8. PubMed ID: 8632731
[No Abstract] [Full Text] [Related]
[Next] [New Search]
